KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Novartis Ag (NVS) Accumulated Depreciation & Amortization (2016 - 2024)

Novartis Ag's Accumulated Depreciation & Amortization history spans 7 years, with the latest figure at -$9.4 billion for Q4 2024.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 0.61% to -$9.4 billion in Q4 2024 year-over-year; TTM through Dec 2024 was -$9.4 billion, a 0.61% increase, with the full-year FY2024 number at -$9.4 billion, up 0.61% from a year prior.
  • Accumulated Depreciation & Amortization hit -$9.4 billion in Q4 2024 for Novartis Ag, up from -$9.5 billion in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for NVS hit a ceiling of -$9.4 billion in Q4 2024 and a floor of -$12.2 billion in Q4 2020.
  • Historically, Accumulated Depreciation & Amortization has averaged -$10.4 billion across 3 years, with a median of -$9.5 billion in 2023.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: plummeted 5443.67% in 2020 and later rose 0.61% in 2024.
  • Tracing NVS's Accumulated Depreciation & Amortization over 3 years: stood at -$12.2 billion in 2020, then grew by 22.4% to -$9.5 billion in 2023, then grew by 0.61% to -$9.4 billion in 2024.
  • Business Quant data shows Accumulated Depreciation & Amortization for NVS at -$9.4 billion in Q4 2024, -$9.5 billion in Q4 2023, and -$12.2 billion in Q4 2020.